CoChat
Sign Up
Cited by 462Health Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

Open access
Griffin, Simon J, Borch-Johnsen, Knut, Davies, Melanie J, Khunti, Kamlesh, Rutten, Guy EHM, Sandbæk, Annelli, Sharp, Stephen J, Simmons, Rebecca K, van den Donk, Maureen, Wareham, Nicholas J, Lauritzen, Torsten·2011·The Lancet
DOI 10.1016/s0140-6736(11)60698-3PMC PMC3136726
Open this paper in CoChat — free account

Abstract

Background Intensive treatment of multiple cardiovascular risk factors can halve mortality among people with established type 2 diabetes. We investigated the effect of early multifactorial treatment after diagnosis by screening.Methods In a pragmatic, cluster-randomised, parallel-group trial done in Denmark, the Netherlands, and the UK, 343 general practices were randomly assigned screening of registered patients aged 40-69 years without known diabetes followed by routine care of diabetes or screening followed by intensive treatment of multiple risk factors. The primary endpoint was first cardiovascular event, including cardiovascular mortality and morbidity, revascularisation, and non-traumatic amputation within 5 years. Patients and staff assessing outcomes were unaware of the practice's study group assignment. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00237549.Findings Primary endpoint data were available for 3055 (99·9%) of 3057 screen-detected patients. The mean age was 60·3 (SD 6·9) years and the mean duration of follow-up was 5·3 (SD 1·6) years. Improvements in cardiovascular risk factors (HbA(1c) and cholesterol concentrations and blood pressure) were slightly but significantly better in the intensive treatment group. The incidence of first cardiovascular event was 7·2% (13·5 per 1000 person-years) in the intensive treatment group and 8·5% (15·9 per 1000 person-years) in the routine care group (hazard ratio 0·83, 95% CI 0·65-1·05), and of all-cause mortality 6·2% (11·6 per 1000 person-years) and 6·7% (12·5 per 1000 person-years; 0·91, 0·69-1·21), respectively.Interpretation An intervention to promote early intensive management of patients with type 2 diabetes was associated with a small, non-significant reduction in the incidence of cardiovascular events and death.Funding National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, Danish Medical Research Council, Aarhus University Research Foundation, Wellcome Trust, UK Medical Research Council, UK NIHR Health Technology Assessment Programme, UK National Health Service R&D, UK National Institute for Health Research, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60698-3

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Rutten, 1999, Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2, Huisarts Wetensch, 42, 67
  2. Rutten, 2006, Dutch Guidelines on Type 2 Diabetes Mellitus. Dutch College of General Practitioners, Huisarts Wetensch, 49, 137

Cited by

Sorted by citations

See all 462

Related

Metadata

Authors
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., & Lauritzen, T.
Affiliations
  • University of Cambridge (GB)
  • University of Leicester (GB)
  • University Medical Center Utrecht (NL)
  • Aarhus University (DK)
  • Wellcome/MRC Institute of Metabolic Science (GB)
Corresponding author
Griffin, Simon J
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-07
Volume
378
Issue
9786
Pages
156-167
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(11)60698-3
PMC
PMC3136726
OpenAlex
W2146392529
Cited by
462
References
43
Citations by year
2026: 7 · 2025: 12 · 2024: 17 · 2023: 14 · 2022: 21 · 2021: 18 · 2020: 35 · 2019: 31 · 2018: 30 · 2017: 38 · 2016: 30 · 2015: 49 · 2014: 46 · 2013: 46 · 2012: 56
FWCI
50.01
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders
  • the Wellcome Trust (G061895)
  • the Medical Research Council (G0001164)
  • the NIHR Health Technology Assessment Programme (08/116/300)
  • National Health Service R&D support funding (RP-PG-0606-1259)
  • Department of Health and ad hoc Support Sciences, the NIHR Health Technology Assessment Programme (08/116/300)
  • the Department of Health NIHR Programme Grant funding scheme (RP-PG-0606-1272)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, cardiovascular risk management, diabetes screening, cardiovascular events, cardiovascular mortality, all-cause mortality, revascularization, non-traumatic amputation, HbA1c, blood pressure, cholesterol, general practice, primary prevention, secondary prevention, risk stratification
MeSH terms
Aged, Denmark, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, United Kingdom, Humans, Hypoglycemic Agents, Male, Mass Screening, Middle Aged, Netherlands, Risk Factors, Cluster Analysis, Outcome Assessment, Health Care, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review